Emmaus Life Sciences Net Income 2006-2021 | EMMA

Emmaus Life Sciences net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Emmaus Life Sciences Annual Net Income
(Millions of US $)
2020 $1
2019 $-55
2018 $-73
2018 $-10
2017 $-7
2016 $-6
2015 $-3
2014 $-3
2013 $-11
2012 $-3
2011 $-9
2010 $-8
2009 $-9
2008 $-5
2007 $-5
2007 $-3
2006 $-3
Emmaus Life Sciences Quarterly Net Income
(Millions of US $)
2021-06-30 $2
2021-03-31 $-8
2020-12-31 $-0
2020-09-30 $6
2020-06-30 $-9
2020-03-31 $6
2019-12-31 $-2
2019-09-30 $-18
2019-06-30 $-17
2019-03-31 $-17
2018-12-31 $-2
2018-09-30 $15
2018-06-30 $-3
2018-03-31 $-3
2017-12-31 $-3
2017-09-30
2017-06-30 $-2
2017-03-31 $-1
2016-12-31 $-1
2016-09-30
2016-06-30 $-1
2016-03-31 $-0
2015-12-31 $-3
2015-09-30
2015-06-30 $-1
2015-03-31 $-1
2014-12-31 $-1
2014-09-30
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $0
2013-09-30
2013-06-30 $-1
2013-03-31 $-2
2012-12-31 $-1
2012-09-30
2012-06-30 $4
2012-03-31 $-8
2011-12-31 $-3
2011-09-30
2011-06-30 $1
2011-03-31 $-7
2010-12-31 $-0
2010-09-30
2010-06-30 $-2
2010-03-31 $-1
2009-12-31 $-2
2009-09-30
2009-06-30 $-2
2009-03-31 $-1
2008-12-31 $-1
2008-09-30 $-1
2008-06-30 $-2
2008-03-31 $-1
2007-12-31 $-1
2007-09-30
2007-06-30 $-1
2007-03-31 $-1
2006-12-31 $-3
2006-09-30 $-0
2006-06-30 $-0
2006-03-31 $-0
2005-09-30 $-0
2005-06-30 $-0
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.081B $0.023B
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43